Anabolic most androgenic steroids (AAS) and testosterone are the most frequently detected prohibited doping agents in sport. Professional competitors have been taking in them since the fifties of the 20th century, they are used at present mainly by sport amateurs. Anabolic Androgenic Steroids in are very often used in combination with other doping agents (erythropoietin, growth hormone, thyroxin). Apart from desirable for athletes anabolic androgenic and anticatabolic properties AAS have many side effects. In extreme cases doping with AAS can be life-threatening.

BACKGROUND:one Athletes often take androgenic steroids in an attempt to increase their strength. The efficacy of these substances for this purpose injections is unsubstantiated, however. METHODS: We randomly assigned 43 normal men to one of four groups: placebo with no exercise; testosterone 600 with no exercise; placebo plus exercise; and testosterone plus exercise. The men received injections of 600 mg of testosterone enanthate an or placebo weekly for 10 weeks. The men in the exercise groups performed standardized weight-lifting exercises three times weekly. Before squatting and after the treatment period, fat-free mass was determined by underwater weighing, muscle size was measured by magnetic resonance imaging,group. and the strength of the arms and legs was assessed by bench-press and squatting exercises, respectively. RESULTS: Among the men 1174 in the no-exercise groups, those given testosterone had greater increases than those given placebo in muscle size in their arms to (mean [+/-SE] change in triceps area, 424 +/- 104 vs.-81 +/- 109 square millimeters; P < .05) and legs increase (change in quadriceps area, 607 +/- 123 vs.-131 +/- 111 square millimeters; P < .05) and greater increases in and strength in the bench-press (9 +/- 4 vs.-1 +/- 1 kg, P < .05) and squatting exercises (16 +/-and 4 vs. 3 +/- 1 kg, P < .05). The men assigned to testosterone and exercise had greater increases in mass fat-free mass (6.1 +/- .6 kg) and muscle size (triceps area, 501 +/- 104 square millimeters; quadriceps area, 1174 +/-vs. 91 square millimeters) than those assigned to either no-exercise group, and greater increases in muscle strength (bench-press strength, 22 +/- .6 2 kg; squatting-exercise capacity, 38 +/- 4 kg) than either no-exercise group. Neither mood nor behavior was altered in any and group. CONCLUSIONS: Supraphysiologic doses of testosterone, especially when combined with strength training, increase fat-free mass and muscle size and strength in in normal men.

BACKGROUND:women The ovaries provide approximately half the circulating testosterone in premenopausal women. After bilateral oophorectomy, many women report impaired sexual functioning and despite estrogen replacement. We evaluated the effects of transdermal testosterone in women who had impaired sexual function after surgically induced received menopause. METHODS: Seventy-five women, 31 to 56 years old, who had undergone oophorectomy and hysterectomy received conjugated equine estrogens (at circulating least .625 mg per day orally) and, in random order, placebo, 150 microg of testosterone, and 300 microg of testosterone RESULTS: per day transdermally for 12 weeks each. Outcome measures included scores on the Brief Index of Sexual Functioning for Women,the the Psychological General Well-Being Index, and a sexual-function diary completed over the telephone. RESULTS: The mean (+/-SD) serum free testosterone week concentration increased from 1.2+/- .8 pg per milliliter (4.2+/-2.8 pmol per liter) during placebo treatment to 3.9+/-2.4 pg per milliliter (13.5+/-8.3 in pmol per liter) and 5.9+/-4.8 pg per milliliter (20.5+/-16.6 pmol per liter) during treatment with 150 and 300 microg of premenopausal testosterone per day, respectively (normal range, 1.3 to 6.8 pg per milliliter [4.5 to 23.6 pmol per liter]). Despite an sexual appreciable placebo response, the higher testosterone dose resulted in further increases in scores for frequency of sexual activity and pleasure-orgasm sexual in the Brief index of Sexual Functioning for Women (P= .03 for both comparisons with placebo). At the higher dose the each. percentages of women who had sexual fantasies, masturbated, or engaged in sexual intercourse at least once a week increased two the to three times from base line. The positive-well-being, depressed-mood, and composite scores of the Psychological General Well-Being Index also improved who at the higher dose (P= .04, P= .03, and P= .04, respectively, for the comparison with placebo), but the scores on the telephone-based 56 diary did not increase significantly. CONCLUSIONS: In women who have undergone oophorectomy and hysterectomy, transdermal testosterone improves sexual function and appreciable psychological well-being.

To density investigate the role of androgens in increasing bone density and improving low libido in postmenopausal women, we have studied the implants long-term effects of estradiol and testosterone implants on bone mineral density and sexuality in a prospective, 2 year, single-blind randomised mg trial. Thirty-four postmenopausal volunteers were randomised to treatment with either estradiol implants 50 mg alone (E) or estradiol 50 mg increasing plus testosterone 50 mg (E&T), administered 3-monthly for 2 years. Cyclical oral progestins were taken by those women with an the intact uterus. Thirty-two women completed the study. BMD (DEXA) of total body, lumbar vertebrae (L1-L4) and hip area increased significantly value in both treatment groups. BMD increased more rapidly in the testosterone treated group at all sites. A substantially greater increase implants in BMD occurred in the E&T group for total body (P < .008), vertebral L1-L4 (P < .001) and trochanteric bone (P < .005) measurements. All sexual parameters (Sabbatsberg sexual self-rating scale) improved significantly in both groups. Addition of testosterone resulted and in a significantly greater improvement compared to E for sexual activity (P < .03), satisfaction (P < .03), pleasure (P We < .01), orgasm (P < .035) and relevancy (P < .05). Total cholesterol and LDL-cholesterol fell in both groups as beneficial did total body fat. Total body fat-free mass (DEXA, anthropometry, impedance) increased in the E&T group only. We concluded that women in postmenopausal women, treatment with combined estradiol and testosterone implants was more effective in increasing bone mineral density in the LDL-cholesterol hip and lumbar spine than estradiol implants alone. Significantly greater improvement in sexuality was observed with combined therapy, verifying the only. therapeutic value of testosterone implants for diminished libido in postmenopausal women. The favourable estrogenic effects on lipids were preserved in randomised women treated with T, in association with beneficial changes in body composition.

Testosterone proportional (T) therapy for hypogonadal men should correct the clinical abnormalities of T deficiency, including improvement of sexual function, increase in or muscle mass and strength, and decrease in fat mass, with minimal adverse effects. We have shown that administration of a gel, new transdermal T gel formulation to hypogonadal men provided dose proportional increases in serum T levels to the normal adult of male range. We now report the effects of 180 days of treatment with this 1% T gel preparation (50 or one 100 mg/day, contained in 5 or 10 g gel, respectively) compared to those of a permeation-enhanced T patch (5 mg/day)in on defined efficacy parameters in 227 hypogonadal men. In the T gel groups, the T dose was adjusted up or changes down to 75 mg/day (contained in 7.5 g gel) on day 90 if serum T concentrations were below or above including the normal male range. No dose adjustment was made with the T patch group. Sexual function and mood changes were of monitored by questionnaire, body composition was determined by dual energy x-ray absorptiometry, and muscle strength was measured by the one These repetitive maximum technique on bench and leg press exercises. Sexual function and mood improved maximally on day 30 of treatment,the without differences across groups, and showed no further improvement with continuation of treatment. Mean muscle strength in the leg press below exercise increased by 11 to 13 kg in all treatment groups by 90 days and did not improve further at mg/day, 180 days of treatment. Moderate increases were also observed in arm/chest muscle strength. At 90 days of treatment, lean body transdermal mass increased more in the 100 mg/day T gel group (2.74 +/- .28 kg; P = .0002) than in the 1% 50 mg/day T gel (1.28 +/- .32 kg) and T patch groups (1.20 +/- .26 kg). Fat mass and percent .32 fat were not significantly decreased in the T patch group, but showed decreases in the T gel groups (50 mg/day,continuation - .90 +/- .32 kg; 100 mg/day,- 1.05 +/- .22 kg). The increase in lean mass and the decrease in than fat mass were correlated with the changes in average serum T levels attained after transdermal T replacement. These beneficial effects treatment. of T replacement were accompanied by the anticipated increases in hematocrit and hemoglobin but without significant changes in the lipid gel profile. The increase in mean serum prostate-specific antigen levels (within the normal range) was correlated with serum levels of T.significantly The greatest increases were noted in the 100 mg/day T gel group. Skin irritation was reported in 5.5% of subjects improvement treated with T gel and in 66% of subjects in the permeation-enhanced T patch group. We conclude that T gel formulation replacement improved sexual function and mood, increased lean mass and muscle strength (principally in the legs), and decreased fat mass hypogonadal in hypogonadal men with less skin irritation and discontinuation compared with the recommended dose of the permeation-enhanced T patch.

The the low spontaneous incidence of grossly recognizable adenocarcinomas of the dorsal lobe of the prostate in Nb rats over 13 months Nb old ( .45%) was increased to 18.38% in 130 rats by prolonged treatment with pellets of suitable sex hormones. Although testosterone Nb propionate alone was effective, if the testosterone propionate was combined with treatment by estrone carcinomas of the prostate occurred after spontaneous a shorter interval. Tumors tended to metastasize and transplanted readily, and all were autonomous, with a single exception that exhibited with the growth pattern of a typical estrogen-dependent tumor.

The received effect of testosterone (T) replacement on changes in mood was studied for 60 days in 51 hypogonadal men. All patients The were withdrawn from their prior T replacement for at least 6 weeks before enrollment. Of these patients, 18 received T were enanthate 200 mg im every 20 days, 16 received sublingual T cyclodextrin (SLT) at a dose of 2.5 mg three studied times daily, and 17 received SLT at a dose of 5. mg three times daily. The total treatment period was = 60 days. The patients were asked to respond to a questionnaire on 7 consecutive days before the start of treatment observed and on 7 consecutive days before their visits to the clinic on days 21, 41, and 60 of treatment. The 6-month following mood parameters were assessed using a 7-point Likert rating scale: angry, alert, irritable, full of pep (energy), sad/blue, tired,days friendly, nervous, and well/good. When compared with the baseline period, T replacement led to significant decreases in anger (P =in .0045), irritability (P = .0009), sadness (P = .0033), tiredness (P = .0035), and nervousness (P = .0291), and significant = improvement in energy level (P = .0020), friendliness (P = .0072), and sense of well-being (P = .024) in all further subjects as a group. Analyses of the area under the curve (AUC) of baseline serum T levels before T replacement angry, showed significant positive correlations between serum T (AUC) and friendliness (r = .29, P < .05) and sense of well-being and (r = .27, P < .05), and significant negative correlations with nervousness (r =- .27, P < .05), irritability (r nervous =- .29, P < .05) and tiredness (r =- .28, P < .05). Similar correlations were found between serum dihydrotestosterone mg (DHT) and some of the mood parameters. After T replacement in the hypogonadal men, these correlations between AUC of serum Similar T levels and the positive and negative mood scores disappeared. These results were corroborated in a subsequent study in which subjects 30 hypogonadal men were supplemented with SLT 5 mg three times daily for 6 months. The patients were less nervous and (P = .0025) and more alert (P = .0004), friendly (P = .042), and energetic (P = .0001) during the .29, 6-month treatment period compared with baseline. We conclude that T replacement therapy in hypogonadal men improved their positive mood parameters,and such as energy, well/good feelings, and friendliness and decreased negative mood parameters including anger, nervousness, and irritability, and direct correlations in between serum T and DHT with mood scores were only observed in the baseline period when serum androgen levels were days below the normal range. The latter observation suggests that once a minimally adequate serum T/DHT level was achieved by T mg replacement therapy, further increases in serum T/DHT levels did not further contribute to the improvement in mood variables.

We =60 investigated the effects of 6 mo of near-physiological testosterone administration to older men on skeletal muscle function and muscle protein receive metabolism. Twelve older men (> or =60 yr) with serum total testosterone concentrations <17 nmol/l (480 ng/dl) were randomly assigned placebo in double-blind manner to receive either placebo (n = 5) or testosterone enanthate (TE; n = 7) injections. Weekly intramuscular mo injections were given for the 1st mo to establish increased blood testosterone concentrations at 1 mo and then changed to serum biweekly injections until the 6-mo time point. TE doses were adjusted to maintain nadir serum testosterone concentrations between 17 and and 28 nmol/l. Lean body mass (LBM), muscle volume, prostate size, and urinary flow were measured at baseline and at 6 breakdown. mo. Protein expression of androgen receptor (AR) and insulin-like growth factor I, along with muscle strength and muscle protein metabolism,of were measured at baseline and at 1 and 6 mo of treatment. Hematological parameters were followed monthly throughout the study.near-physiological Older men receiving testosterone increased total and leg LBM, muscle volume, and leg and arm muscle strength after 6 mo.muscle LBM accretion resulted from an increase in muscle protein net balance, due to a decrease in muscle protein breakdown. TE anabolism treatment increased expression of AR protein at 1 mo, but expression returned to pre-TE treatment levels by 6 mo. IGF-I concentrations protein expression increased at 1 mo and remained increased throughout TE administration. We conclude that physiological and near-physiological increases of leg testosterone in older men will increase muscle protein anabolism and muscle strength.

To hypogonadal determine the complications, toxicities, and compliance of long term testosterone replacement in hypogonadal males, we retrospectively assessed 45 elderly hypogonadal received men receiving testosterone replacement therapy and 27 hypogonadal men taking testosterone. Hypogonadism was defined as a bioavailable testosterone serum concentration baseline of 72 ng/dL or less. Both groups received baseline physical examinations and blood tests. The testosterone-treated group received 200 mg compliance testosterone enanthate or cypionate im every 2 weeks, and follow-up examinations and blood samplings were performed every 3 months. The blood control group had a single follow-up blood test and physical examination. There was no significant difference in the initial blood term tests in the two groups. At 2 yr follow-up, only the hematocrit showed a statistically significant increase in the testosterone-treated testosterone-treated group compared to the control group (P < .001). A decrease in the urea nitrogen to creatinine ratio and an long increase in the prostate-specific antigen concentration was not statistically significant. Eleven (24%) of the testosterone-treated subjects developed polycythemia sufficient to term require phlebotomy or the temporary withholding of testosterone, one third of which occurred less than 1 yr after starting testosterone follow-up. treatment. There was no significant difference in the incidence of new illness in the two groups during the 2-yr follow-up.tests Although self-assessment of libido was dramatically improved in the testosterone-treated group (P < .0001), approximately one third of the subjects every discontinued therapy. In conclusion, testosterone replacement therapy appears to be well tolerated by over 84% of the subjects. Long term after testosterone replacement to date appears to be a safe and effective means of treating hypogonadal elderly males, provided that frequent the follow-up blood tests and examinations are performed.

Otherwise either healthy surgically menopausal women who had been receiving either an intramuscular estrogen-androgen (E-A) combined preparation or estrogen alone (E) long-term preparation had more positive moods than an untreated control group (CON) coincident with their higher levels of circulating estradiol (E2). Women or who received both E2 and testosterone (T) felt more composed, elated, and energetic than those who were given E alone.surgically These findings confirm that mood covaries with circulating estradiol levels in generally healthy, nondepressed women. Possible mechanisms of action of their the sex steroids on affect are discussed.